Sign inJoin waitlistJoin the waitlist

Michael Cecchini

Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers · Yale-New Haven Hospital

Credentials: · · · · ·

History

Colorectal Program in the Center for Gastrointestinal Cancers · Yale-New Haven Hospital
Present
GI Clinical Research Team Yale Center for GI Cancers · Yale-New Haven Hospital
Present
Colorectal Program in the Center for Gastrointestinal Cancers
Present

Yale Cancer Center
2015–2017
Hematology and Medical Oncology
Smilow Cancer Hospital
2012–2015
Albert Einstein College of Medicine
2008–2012
University of California, Santa Cruz, Cell, Molecular, and Developmental Biology
2004–2008
University of California
2005–2008

Research

Targeted Therapies in Advanced Gastric Cancer
Review · Current Treatment Options in Oncology · 2020 · 231 citations
Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
BMC Cancer · 2016 · 62 citations
Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
JAMA Network Open · 2023 · 42 citations

Jill Lacy
15 papers
Stacey Stein
12 papers
Kimberly Johung
9 papers
Patricia LoRusso
9 papers
Jeremy Kortmansky
8 papers
JS
Jeffrey Sklar
7 papers
Raghav Sundar
7 papers · 7 as a resident
JE
Joseph Eder
6 papers
Joseph Miccio
6 papers · 6 as a resident
JB
Justin Bader
6 papers · 6 as a resident
Kiran Turaga
6 papers
Princy Gupta
6 papers

Grants

Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal Cancer
National Cancer Institute · K08
Contact PI · $1.3M · Yale University
2021–2026

Clinical trials

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Principal investigator · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2023–2027
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
Principal investigator · Completed · Phase 1
Sirnaomics
2021–2024
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Principal investigator · Completed · Phase 2
Yale University
2020–2023
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
Principal investigator · Completed · Phase 1, Phase 2
National Cancer Institute (NCI)
2018–2025